Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A Reduced Dose of Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss
NCT06909123Phase 2Withdrawn
- Sponsor
- Stanford University
- Start
- Jul 2026
- Primary completion
- Jan 2027
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of cabergoline in lactation (2 arms), sponsored by Stanford University. Primary endpoint: Number of participants with serum prolactin level less than 23 ng/mL at Day 4. Planned start Jul 2026; status: withdrawn.
02
Drugs
cabergoline
03
Conditions
lactation
Beyond the preview
Go deeper on NCT06909123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06909123.